Literature DB >> 16946210

Patterns and progress in ovarian cancer over 14 years.

John K Chan1, Michael K Cheung, Amreen Husain, Nelson N Teng, Dee West, Alice S Whittemore, Jonathan S Berek, Kathryn Osann.   

Abstract

OBJECTIVE: To estimate the change in survival rates of women with ovarian cancer during the past 14 years.
METHODS: Women diagnosed with epithelial, germ cell, sarcomas, and sex-cord stromal ovarian tumors were identified from the Surveillance Epidemiology and End Results Database. Demographic and clinicopathologic factors, and survival information were extracted and tested using chi 2 and Kaplan-Meier and Cox regression analyses.
RESULTS: A total of 30,246 women were diagnosed with ovarian cancer, including 26,753 non-clear cell epithelial, 1,411 clear cell, 818 sarcoma, 778 germ cell, and 486 sex-cord stromal tumors. The 5-year disease-specific survival rate across 1988-1992 and 1993-1997 improved from 45.4% to 48.6% (P < .001). The corresponding estimates show increases for non-clear cell epithelial carcinoma from 42.5% to 45.8% (P < .001), and for sarcomas from 33.5% to 38.8% (P = .07). However, improvements were not observed in those with clear cell, 64.3% to 63.9% (P = .82), and sex-cord stromal, 89.7% to 85.7% (P = .18), tumors of the ovary. In multivariable analyses, younger age, early stage, favorable histologic cell types, low-grade tumors, standard surgery, and recent time interval from 1993-1997 were independent prognostic factors for improved survival.
CONCLUSION: In this large population-based study, there has been some improvement in the overall survival of women with ovarian cancers during a 14-year period. However, new treatment strategies are warranted for those with epithelial cancer and sarcomas of the ovary, given their overall poor prognosis. These results from our updated analyses might help to counsel women diagnosed with ovarian cancers.

Entities:  

Mesh:

Year:  2006        PMID: 16946210     DOI: 10.1097/01.AOG.0000231680.58221.a7

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  55 in total

1.  Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model.

Authors:  Amelie M Lutz; Sunitha V Bachawal; Charles W Drescher; Marybeth A Pysz; Jürgen K Willmann; Sanjiv Sam Gambhir
Journal:  Clin Cancer Res       Date:  2014-01-03       Impact factor: 12.531

2.  3-cinnamoyl-4-hydroxy-6-methyl-2H-pyran-2-one (CHP) inhibits human ovarian cell proliferation by inducing apoptosis.

Authors:  Qiong-Yu Lan; Que-Ling Liu; Jing Cai; An-Wen Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

3.  MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.

Authors:  Wen Qin; Wei Xie; Qinglin He; Tianwei Sun; Chaoguo Meng; Kunling Yang; Yuanfu Luo; Dongmei Yang
Journal:  Exp Ther Med       Date:  2017-11-17       Impact factor: 2.447

4.  A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

Authors:  John K Chan; William Brady; Bradley J Monk; Jubilee Brown; Mark S Shahin; Peter G Rose; Jae-Hoon Kim; Angeles Alvarez Secord; Joan L Walker; David M Gershenson
Journal:  Gynecol Oncol       Date:  2018-06-18       Impact factor: 5.482

5.  TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.

Authors:  Jeremy Chien; Hugues Sicotte; Jian-Bing Fan; Sean Humphray; Julie M Cunningham; Kimberly R Kalli; Ann L Oberg; Steven N Hart; Ying Li; Jaime I Davila; Saurabh Baheti; Chen Wang; Sabine Dietmann; Elizabeth J Atkinson; Yan W Asmann; Debra A Bell; Takayo Ota; Yaman Tarabishy; Rui Kuang; Marina Bibikova; R Keira Cheetham; Russell J Grocock; Elizabeth M Swisher; John Peden; David Bentley; Jean-Pierre A Kocher; Scott H Kaufmann; Lynn C Hartmann; Viji Shridhar; Ellen L Goode
Journal:  Nucleic Acids Res       Date:  2015-04-27       Impact factor: 16.971

6.  Ranked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients.

Authors:  Vanessa L Beesley; Alexandra M Clavarino; Penelope M Webb; David K Wyld; Alessandra B Francesconi; Keith R Horwood; James D Doecke; Colleen A Loos; Adele C Green
Journal:  Support Care Cancer       Date:  2009-09-24       Impact factor: 3.603

7.  Population-based study of ovarian cancer in Côte d'Or: prognostic factors and trends in relative survival rates over the last 20 years.

Authors:  Zeinab Hamidou; Sylvain Causeret; Tienhan S Dabakuyo; Julie Gentil; Laurent Arnould; Patrick Roignot; Thierry Altwegg; Marie-Laure Poillot; Franck Bonnetain; Patrick Arveux
Journal:  BMC Cancer       Date:  2010-11-10       Impact factor: 4.430

8.  Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas.

Authors:  Chi-An Chen; Ying-Cheng Chiang; Ming-Cheng Chang; Yu-Hao Hu; San-Lin You; Yeu-Yao Kevin Cheng; Cheng-Yang Chou; Wen-Fang Cheng
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

9.  Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers.

Authors:  Jan Rohozinski; Matthew L Anderson; Russell E Broaddus; Creighton L Edwards; Colin E Bishop
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

10.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.